Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy
Background Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer evolutionary tree using bulk-targeted deep sequencing to explore the impact of sequential and co-occurring somatic mutations on patients with stag...
Saved in:
| Published in | BMC cancer Vol. 21; no. 1; pp. 217 - 11 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
02.03.2021
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-2407 1471-2407 |
| DOI | 10.1186/s12885-021-07926-1 |
Cover
| Abstract | Background
Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer evolutionary tree using bulk-targeted deep sequencing to explore the impact of sequential and co-occurring somatic mutations on patients with stage III colorectal cancer (CRC).
Methods
A total of 108 stage III CRC patients from National Cheng Kung University Hospital (NCKUH) were recruited for this study between Jan. 2014 and Jan. 2019. Clinical information and tumor-targeted deep sequencing data were collected. Phylogenetic trees were reconstructed for evolutionary trajectories. We used a machine learning model for survival analysis.
Results
Six sequential somatic mutations stratified patients into seven subgroups based on survival. Patients carrying sequential germline followed by DNA damage response-related
ATM
or
BRCA2
somatic mutations or non-
TP53, APC
somatic mutations had a better outcome than those without such mutations. The 4-year recurrence-free survival (RFS) probability was 88% in the low-risk group (G1) and 46% in the high-risk group (G2) (log-rank
p
-value 2e-05). The predictive efficacy by the area under the curve (AUC) was 0.73, 0.7, 0.797, and 0.88 at 2, 4, 6, and 8 years, respectively. The mutation status of mismatch repair (MMR) genes was not associated with RFS. Different genomic features were found between the groups. The orders of
APC
,
KRAS
and
APC
,
BRCA2
sequential somatic mutations were associated with clinical outcomes. The occurrence of somatic mutations in
BRCA2
, such as
TP53
somatic mutations, affected recurrence-free survival.
Conclusions
According to the evolution model, DNA damage response (DDR)-related
ATM
or
BRCA2
somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin-based chemotherapy. The sequential order and co-occurring DDR somatic mutations are associated with recurrence-free survival. |
|---|---|
| AbstractList | Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer evolutionary tree using bulk-targeted deep sequencing to explore the impact of sequential and co-occurring somatic mutations on patients with stage III colorectal cancer (CRC). A total of 108 stage III CRC patients from National Cheng Kung University Hospital (NCKUH) were recruited for this study between Jan. 2014 and Jan. 2019. Clinical information and tumor-targeted deep sequencing data were collected. Phylogenetic trees were reconstructed for evolutionary trajectories. We used a machine learning model for survival analysis. Six sequential somatic mutations stratified patients into seven subgroups based on survival. Patients carrying sequential germline followed by DNA damage response-related ATM or BRCA2 somatic mutations or non-TP53, APC somatic mutations had a better outcome than those without such mutations. The 4-year recurrence-free survival (RFS) probability was 88% in the low-risk group (G1) and 46% in the high-risk group (G2) (log-rank p-value 2e-05). The predictive efficacy by the area under the curve (AUC) was 0.73, 0.7, 0.797, and 0.88 at 2, 4, 6, and 8 years, respectively. The mutation status of mismatch repair (MMR) genes was not associated with RFS. Different genomic features were found between the groups. The orders of APC, KRAS and APC, BRCA2 sequential somatic mutations were associated with clinical outcomes. The occurrence of somatic mutations in BRCA2, such as TP53 somatic mutations, affected recurrence-free survival. According to the evolution model, DNA damage response (DDR)-related ATM or BRCA2 somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin-based chemotherapy. The sequential order and co-occurring DDR somatic mutations are associated with recurrence-free survival. Background Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer evolutionary tree using bulk-targeted deep sequencing to explore the impact of sequential and co-occurring somatic mutations on patients with stage III colorectal cancer (CRC). Methods A total of 108 stage III CRC patients from National Cheng Kung University Hospital (NCKUH) were recruited for this study between Jan. 2014 and Jan. 2019. Clinical information and tumor-targeted deep sequencing data were collected. Phylogenetic trees were reconstructed for evolutionary trajectories. We used a machine learning model for survival analysis. Results Six sequential somatic mutations stratified patients into seven subgroups based on survival. Patients carrying sequential germline followed by DNA damage response-related ATM or BRCA2 somatic mutations or non- TP53, APC somatic mutations had a better outcome than those without such mutations. The 4-year recurrence-free survival (RFS) probability was 88% in the low-risk group (G1) and 46% in the high-risk group (G2) (log-rank p -value 2e-05). The predictive efficacy by the area under the curve (AUC) was 0.73, 0.7, 0.797, and 0.88 at 2, 4, 6, and 8 years, respectively. The mutation status of mismatch repair (MMR) genes was not associated with RFS. Different genomic features were found between the groups. The orders of APC , KRAS and APC , BRCA2 sequential somatic mutations were associated with clinical outcomes. The occurrence of somatic mutations in BRCA2 , such as TP53 somatic mutations, affected recurrence-free survival. Conclusions According to the evolution model, DNA damage response (DDR)-related ATM or BRCA2 somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin-based chemotherapy. The sequential order and co-occurring DDR somatic mutations are associated with recurrence-free survival. Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer evolutionary tree using bulk-targeted deep sequencing to explore the impact of sequential and co-occurring somatic mutations on patients with stage III colorectal cancer (CRC).BACKGROUNDCertain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer evolutionary tree using bulk-targeted deep sequencing to explore the impact of sequential and co-occurring somatic mutations on patients with stage III colorectal cancer (CRC).A total of 108 stage III CRC patients from National Cheng Kung University Hospital (NCKUH) were recruited for this study between Jan. 2014 and Jan. 2019. Clinical information and tumor-targeted deep sequencing data were collected. Phylogenetic trees were reconstructed for evolutionary trajectories. We used a machine learning model for survival analysis.METHODSA total of 108 stage III CRC patients from National Cheng Kung University Hospital (NCKUH) were recruited for this study between Jan. 2014 and Jan. 2019. Clinical information and tumor-targeted deep sequencing data were collected. Phylogenetic trees were reconstructed for evolutionary trajectories. We used a machine learning model for survival analysis.Six sequential somatic mutations stratified patients into seven subgroups based on survival. Patients carrying sequential germline followed by DNA damage response-related ATM or BRCA2 somatic mutations or non-TP53, APC somatic mutations had a better outcome than those without such mutations. The 4-year recurrence-free survival (RFS) probability was 88% in the low-risk group (G1) and 46% in the high-risk group (G2) (log-rank p-value 2e-05). The predictive efficacy by the area under the curve (AUC) was 0.73, 0.7, 0.797, and 0.88 at 2, 4, 6, and 8 years, respectively. The mutation status of mismatch repair (MMR) genes was not associated with RFS. Different genomic features were found between the groups. The orders of APC, KRAS and APC, BRCA2 sequential somatic mutations were associated with clinical outcomes. The occurrence of somatic mutations in BRCA2, such as TP53 somatic mutations, affected recurrence-free survival.RESULTSSix sequential somatic mutations stratified patients into seven subgroups based on survival. Patients carrying sequential germline followed by DNA damage response-related ATM or BRCA2 somatic mutations or non-TP53, APC somatic mutations had a better outcome than those without such mutations. The 4-year recurrence-free survival (RFS) probability was 88% in the low-risk group (G1) and 46% in the high-risk group (G2) (log-rank p-value 2e-05). The predictive efficacy by the area under the curve (AUC) was 0.73, 0.7, 0.797, and 0.88 at 2, 4, 6, and 8 years, respectively. The mutation status of mismatch repair (MMR) genes was not associated with RFS. Different genomic features were found between the groups. The orders of APC, KRAS and APC, BRCA2 sequential somatic mutations were associated with clinical outcomes. The occurrence of somatic mutations in BRCA2, such as TP53 somatic mutations, affected recurrence-free survival.According to the evolution model, DNA damage response (DDR)-related ATM or BRCA2 somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin-based chemotherapy. The sequential order and co-occurring DDR somatic mutations are associated with recurrence-free survival.CONCLUSIONSAccording to the evolution model, DNA damage response (DDR)-related ATM or BRCA2 somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin-based chemotherapy. The sequential order and co-occurring DDR somatic mutations are associated with recurrence-free survival. Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer evolutionary tree using bulk-targeted deep sequencing to explore the impact of sequential and co-occurring somatic mutations on patients with stage III colorectal cancer (CRC). A total of 108 stage III CRC patients from National Cheng Kung University Hospital (NCKUH) were recruited for this study between Jan. 2014 and Jan. 2019. Clinical information and tumor-targeted deep sequencing data were collected. Phylogenetic trees were reconstructed for evolutionary trajectories. We used a machine learning model for survival analysis. Six sequential somatic mutations stratified patients into seven subgroups based on survival. Patients carrying sequential germline followed by DNA damage response-related ATM or BRCA2 somatic mutations or non-TP53, APC somatic mutations had a better outcome than those without such mutations. The 4-year recurrence-free survival (RFS) probability was 88% in the low-risk group (G1) and 46% in the high-risk group (G2) (log-rank p-value 2e-05). The predictive efficacy by the area under the curve (AUC) was 0.73, 0.7, 0.797, and 0.88 at 2, 4, 6, and 8 years, respectively. The mutation status of mismatch repair (MMR) genes was not associated with RFS. Different genomic features were found between the groups. The orders of APC, KRAS and APC, BRCA2 sequential somatic mutations were associated with clinical outcomes. The occurrence of somatic mutations in BRCA2, such as TP53 somatic mutations, affected recurrence-free survival. According to the evolution model, DNA damage response (DDR)-related ATM or BRCA2 somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin-based chemotherapy. The sequential order and co-occurring DDR somatic mutations are associated with recurrence-free survival. Abstract Background Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer evolutionary tree using bulk-targeted deep sequencing to explore the impact of sequential and co-occurring somatic mutations on patients with stage III colorectal cancer (CRC). Methods A total of 108 stage III CRC patients from National Cheng Kung University Hospital (NCKUH) were recruited for this study between Jan. 2014 and Jan. 2019. Clinical information and tumor-targeted deep sequencing data were collected. Phylogenetic trees were reconstructed for evolutionary trajectories. We used a machine learning model for survival analysis. Results Six sequential somatic mutations stratified patients into seven subgroups based on survival. Patients carrying sequential germline followed by DNA damage response-related ATM or BRCA2 somatic mutations or non-TP53, APC somatic mutations had a better outcome than those without such mutations. The 4-year recurrence-free survival (RFS) probability was 88% in the low-risk group (G1) and 46% in the high-risk group (G2) (log-rank p-value 2e-05). The predictive efficacy by the area under the curve (AUC) was 0.73, 0.7, 0.797, and 0.88 at 2, 4, 6, and 8 years, respectively. The mutation status of mismatch repair (MMR) genes was not associated with RFS. Different genomic features were found between the groups. The orders of APC, KRAS and APC, BRCA2 sequential somatic mutations were associated with clinical outcomes. The occurrence of somatic mutations in BRCA2, such as TP53 somatic mutations, affected recurrence-free survival. Conclusions According to the evolution model, DNA damage response (DDR)-related ATM or BRCA2 somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin-based chemotherapy. The sequential order and co-occurring DDR somatic mutations are associated with recurrence-free survival. Background Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer evolutionary tree using bulk-targeted deep sequencing to explore the impact of sequential and co-occurring somatic mutations on patients with stage III colorectal cancer (CRC). Methods A total of 108 stage III CRC patients from National Cheng Kung University Hospital (NCKUH) were recruited for this study between Jan. 2014 and Jan. 2019. Clinical information and tumor-targeted deep sequencing data were collected. Phylogenetic trees were reconstructed for evolutionary trajectories. We used a machine learning model for survival analysis. Results Six sequential somatic mutations stratified patients into seven subgroups based on survival. Patients carrying sequential germline followed by DNA damage response-related ATM or BRCA2 somatic mutations or non-TP53, APC somatic mutations had a better outcome than those without such mutations. The 4-year recurrence-free survival (RFS) probability was 88% in the low-risk group (G1) and 46% in the high-risk group (G2) (log-rank p-value 2e-05). The predictive efficacy by the area under the curve (AUC) was 0.73, 0.7, 0.797, and 0.88 at 2, 4, 6, and 8 years, respectively. The mutation status of mismatch repair (MMR) genes was not associated with RFS. Different genomic features were found between the groups. The orders of APC, KRAS and APC, BRCA2 sequential somatic mutations were associated with clinical outcomes. The occurrence of somatic mutations in BRCA2, such as TP53 somatic mutations, affected recurrence-free survival. Conclusions According to the evolution model, DNA damage response (DDR)-related ATM or BRCA2 somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin-based chemotherapy. The sequential order and co-occurring DDR somatic mutations are associated with recurrence-free survival. Keywords: Sequential somatic mutations, DNA damage response gene, Colorectal cancer, Tumor heterogeneity, Tumor evolution Background Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer evolutionary tree using bulk-targeted deep sequencing to explore the impact of sequential and co-occurring somatic mutations on patients with stage III colorectal cancer (CRC). Methods A total of 108 stage III CRC patients from National Cheng Kung University Hospital (NCKUH) were recruited for this study between Jan. 2014 and Jan. 2019. Clinical information and tumor-targeted deep sequencing data were collected. Phylogenetic trees were reconstructed for evolutionary trajectories. We used a machine learning model for survival analysis. Results Six sequential somatic mutations stratified patients into seven subgroups based on survival. Patients carrying sequential germline followed by DNA damage response-related ATM or BRCA2 somatic mutations or non-TP53, APC somatic mutations had a better outcome than those without such mutations. The 4-year recurrence-free survival (RFS) probability was 88% in the low-risk group (G1) and 46% in the high-risk group (G2) (log-rank p-value 2e-05). The predictive efficacy by the area under the curve (AUC) was 0.73, 0.7, 0.797, and 0.88 at 2, 4, 6, and 8 years, respectively. The mutation status of mismatch repair (MMR) genes was not associated with RFS. Different genomic features were found between the groups. The orders of APC, KRAS and APC, BRCA2 sequential somatic mutations were associated with clinical outcomes. The occurrence of somatic mutations in BRCA2, such as TP53 somatic mutations, affected recurrence-free survival. Conclusions According to the evolution model, DNA damage response (DDR)-related ATM or BRCA2 somatic mutations are promising biomarkers for assessing the response of stage III CRC patients to oxaliplatin-based chemotherapy. The sequential order and co-occurring DDR somatic mutations are associated with recurrence-free survival. |
| ArticleNumber | 217 |
| Audience | Academic |
| Author | Shen, Meng-Ru Pan, Chien-Chang Lin, Peng-Chan Yeh, Yu-Min Chen, Po-Chuan Lin, Bo-Wen Chan, Ren-Hao |
| Author_xml | – sequence: 1 givenname: Peng-Chan surname: Lin fullname: Lin, Peng-Chan organization: Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Department of Genomic Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Department of Computer Science and Information Engineering, College of Electrical Engineering and Computer Science, National Cheng Kung University – sequence: 2 givenname: Yu-Min surname: Yeh fullname: Yeh, Yu-Min organization: Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University – sequence: 3 givenname: Ren-Hao surname: Chan fullname: Chan, Ren-Hao organization: Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University – sequence: 4 givenname: Bo-Wen surname: Lin fullname: Lin, Bo-Wen organization: Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University – sequence: 5 givenname: Po-Chuan surname: Chen fullname: Chen, Po-Chuan organization: Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University – sequence: 6 givenname: Chien-Chang surname: Pan fullname: Pan, Chien-Chang organization: Department of Genomic Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Department of Computer Science and Information Engineering, College of Electrical Engineering and Computer Science, National Cheng Kung University, Department of Pharmacology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University – sequence: 7 givenname: Meng-Ru surname: Shen fullname: Shen, Meng-Ru email: mrshen@mail.ncku.edu.tw organization: Department of Pharmacology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Graduate Institute of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33653301$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk91u1DAQhSNURH_gBbhAkZAQXKTEjhPHN0hV-VupAon23pp1ZrNeOXawnaV9Jl4Sb7e03QpVKBeJJud848yZHGZ71lnMspekPCakbd4HQtu2LkpKipIL2hTkSXZAGCcFZSXfu_e8nx2GsCpLwtuyfZbtV1VTV1VJDrLf5_hzQhs1mBxslytXOKUm77Xt84_fTvIOBugx9xhGZwPmPVqMWuXDFCHqVMr1MIKKeZj8Wq8TRts8xI1nNpslnnEeVUx1BVahz8dkSw1DQirU600f6FbTGmzM3SUYPZqksMUcAqbzLHFwcYkexqvn2dMFmIAvbu5H2cXnTxenX4uz719mpydnhWo4jUVLFOXIFHYd7xgjFAhhjCqsRLtoWkUrwoRqOsVZVXOEkvG5ACRUqLorRXWUzbbYzsFKjl4P4K-kAy2vC873EnwagUFZUU7KuuOtaCsGINpGiIXABuo5r7moE6vasiY7wtUvMOYWSEq5SVFuU5QpRXmdoiTJ9WHrGqf5gJ1K4_Jgdo6y-8bqpezdWiZ_xRqWAG9vAN6leEOUgw4KjQGLbgqSMtHQqhV00-v1A-nKTd6m-Upal1SUTS3YnaqH9NnaLlzqqzZQedLUNaWJtmEd_0OVrg4HrdLyLnSq7xje7RiSJuJl7GEKQc7Of-xq39zTLhFMXAZnpusl3BW-uj-927H9XfokaLcC5V0IHhdS6e0yp-Nq83gy9IH1v-K8WYIwbn4r9HcjfsT1B9h7NVw |
| CitedBy_id | crossref_primary_10_1016_j_cancergen_2022_10_002 crossref_primary_10_1016_j_mocell_2025_100200 crossref_primary_10_1002_cam4_5716 crossref_primary_10_4103_crst_crst_260_23 crossref_primary_10_3390_genes14061270 crossref_primary_10_3389_fonc_2025_1470939 crossref_primary_10_3389_fsurg_2024_1398289 crossref_primary_10_3389_fcvm_2021_721107 crossref_primary_10_1186_s12885_023_10940_0 crossref_primary_10_3390_cancers14030817 crossref_primary_10_3390_cancers13133130 crossref_primary_10_1080_00365521_2021_2022189 crossref_primary_10_1016_j_gene_2025_149433 |
| Cites_doi | 10.1002/1878-0261.12467 10.1038/s41598-019-39525-3 10.1038/nrc1074 10.1016/j.cell.2011.03.026 10.1038/nature08467 10.1101/cshperspect.a027060 10.1038/nrclinonc.2017.166 10.1056/NEJMoa1412098 10.1016/j.celrep.2018.03.076 10.1038/s41592-018-0108-x 10.1158/1078-0432.CCR-19-2409 10.1016/j.ccell.2018.11.009 10.1007/s00432-020-03237-3 10.4161/cbt.12.8.17169 10.1016/S1470-2045(11)70335-7 10.1158/1078-0432.CCR-17-1841 10.1038/s41598-019-40571-0 10.1371/journal.pgen.1002700 10.1371/journal.pcbi.1003665 10.1038/nrm.2016.48 10.1038/nm.4291 10.3390/cells9092110 10.1053/j.gastro.2014.09.041 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1186/s12885-021-07926-1 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 6 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_327105d789834aa98699f9e6a5b75795 10.1186/s12885-021-07926-1 PMC7923464 A655222381 33653301 10_1186_s12885_021_07926_1 |
| Genre | Journal Article |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI 7X8 5PM 2VQ 4.4 ADTOC AHSBF C1A EJD H13 IPNFZ LGEZI LOTEE NADUK NXXTH RIG UNPAY |
| ID | FETCH-LOGICAL-c672t-81c27e4cedd7d4412a11442ce398f68c23149c6dc74357ea047b9ae129c5d093 |
| IEDL.DBID | UNPAY |
| ISSN | 1471-2407 |
| IngestDate | Fri Oct 03 12:53:19 EDT 2025 Sun Oct 26 04:08:10 EDT 2025 Tue Sep 30 16:41:36 EDT 2025 Fri Sep 05 11:03:20 EDT 2025 Tue Oct 07 05:28:27 EDT 2025 Mon Oct 20 21:53:40 EDT 2025 Mon Oct 20 16:22:31 EDT 2025 Thu Oct 16 14:24:20 EDT 2025 Thu May 22 21:15:46 EDT 2025 Thu Jan 02 22:56:06 EST 2025 Wed Oct 01 05:06:42 EDT 2025 Thu Apr 24 23:10:04 EDT 2025 Sat Sep 06 07:17:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Tumor heterogeneity Tumor evolution Sequential somatic mutations DNA damage response gene Colorectal cancer |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c672t-81c27e4cedd7d4412a11442ce398f68c23149c6dc74357ea047b9ae129c5d093 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-021-07926-1 |
| PMID | 33653301 |
| PQID | 2502906594 |
| PQPubID | 44074 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_327105d789834aa98699f9e6a5b75795 unpaywall_primary_10_1186_s12885_021_07926_1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7923464 proquest_miscellaneous_2496238921 proquest_journals_2502906594 gale_infotracmisc_A655222381 gale_infotracacademiconefile_A655222381 gale_incontextgauss_ISR_A655222381 gale_healthsolutions_A655222381 pubmed_primary_33653301 crossref_citationtrail_10_1186_s12885_021_07926_1 crossref_primary_10_1186_s12885_021_07926_1 springer_journals_10_1186_s12885_021_07926_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-02 |
| PublicationDateYYYYMMDD | 2021-03-02 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC cancer |
| PublicationTitleAbbrev | BMC Cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | S Arena (7926_CR25) 2020; 26 KC Arbour (7926_CR8) 2018; 24 AJ Levine (7926_CR4) 2019; 35 CA Ortmann (7926_CR26) 2015; 372 DA Haber (7926_CR2) 2011; 145 PC Lin (7926_CR16) 2020; 10 G Caravagna (7926_CR13) 2018; 15 I Dagogo-Jack (7926_CR1) 2018; 15 DG Kent (7926_CR5) 2017; 7 FA Sinicrope (7926_CR22) 2015; 148 G Randon (7926_CR24) 2019; 9 SP Jackson (7926_CR23) 2009; 461 DB Longley (7926_CR18) 2003; 3 M Iwaizumi (7926_CR19) 2011; 12 NM Reilly (7926_CR11) 2019; 13 EJ Atkinson (7926_CR14) 2000; 61 E Roger (7926_CR17) 2020; 9 CA Miller (7926_CR12) 2014; 10 M Herbet (7926_CR6) 2012; 8 PM Bruno (7926_CR20) 2017; 23 PC Lin (7926_CR10) 2019; 9 TA Knijnenburg (7926_CR9) 2018; 23 Y Zhao (7926_CR7) 2020; 146 NC Turner (7926_CR3) 2012; 13 T Hothorn (7926_CR15) 2015; 16 R Ceccaldi (7926_CR21) 2016; 17 |
| References_xml | – volume: 13 start-page: 681 year: 2019 ident: 7926_CR11 publication-title: Mol Oncol doi: 10.1002/1878-0261.12467 – volume: 9 start-page: 2858 year: 2019 ident: 7926_CR24 publication-title: Sci Rep doi: 10.1038/s41598-019-39525-3 – volume: 3 start-page: 330 year: 2003 ident: 7926_CR18 publication-title: Nat Rev Cancer doi: 10.1038/nrc1074 – volume: 145 start-page: 19 year: 2011 ident: 7926_CR2 publication-title: Cell. doi: 10.1016/j.cell.2011.03.026 – volume: 461 start-page: 1071 year: 2009 ident: 7926_CR23 publication-title: Nature. doi: 10.1038/nature08467 – volume: 16 start-page: 3905 year: 2015 ident: 7926_CR15 publication-title: J Mach Learn Res – volume: 7 start-page: a027060 year: 2017 ident: 7926_CR5 publication-title: Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a027060 – volume: 10 start-page: 2348 year: 2020 ident: 7926_CR16 publication-title: Front Oncol – volume: 15 start-page: 81 year: 2018 ident: 7926_CR1 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2017.166 – volume: 372 start-page: 601 year: 2015 ident: 7926_CR26 publication-title: N Engl J Med doi: 10.1056/NEJMoa1412098 – volume: 23 start-page: 239 year: 2018 ident: 7926_CR9 publication-title: Cell Rep doi: 10.1016/j.celrep.2018.03.076 – volume: 15 start-page: 707 year: 2018 ident: 7926_CR13 publication-title: Nat Methods doi: 10.1038/s41592-018-0108-x – volume: 26 start-page: 1372 year: 2020 ident: 7926_CR25 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-2409 – volume: 35 start-page: 10 year: 2019 ident: 7926_CR4 publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.11.009 – volume: 146 start-page: 1781 year: 2020 ident: 7926_CR7 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-020-03237-3 – volume: 12 start-page: 756 year: 2011 ident: 7926_CR19 publication-title: Cancer Biol Ther doi: 10.4161/cbt.12.8.17169 – volume: 13 start-page: e178 year: 2012 ident: 7926_CR3 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70335-7 – volume: 24 start-page: 334 year: 2018 ident: 7926_CR8 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-1841 – volume: 9 start-page: 3931 year: 2019 ident: 7926_CR10 publication-title: Sci Rep doi: 10.1038/s41598-019-40571-0 – volume: 8 start-page: e1002700 year: 2012 ident: 7926_CR6 publication-title: PLoS Genet doi: 10.1371/journal.pgen.1002700 – volume: 10 start-page: e1003665 year: 2014 ident: 7926_CR12 publication-title: PLoS Comput Biol doi: 10.1371/journal.pcbi.1003665 – volume: 17 start-page: 337 year: 2016 ident: 7926_CR21 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm.2016.48 – volume: 23 start-page: 461 year: 2017 ident: 7926_CR20 publication-title: Nat Med doi: 10.1038/nm.4291 – volume: 61 start-page: 33 year: 2000 ident: 7926_CR14 publication-title: Mayo Clin Sect Biostat Tech Rep – volume: 9 start-page: 2110 year: 2020 ident: 7926_CR17 publication-title: Cells doi: 10.3390/cells9092110 – volume: 148 start-page: 88 year: 2015 ident: 7926_CR22 publication-title: Gastroenterology. doi: 10.1053/j.gastro.2014.09.041 |
| SSID | ssj0017808 |
| Score | 2.3877792 |
| Snippet | Background
Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer... Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer evolutionary... Background Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a cancer... Abstract Background Certain sequences of genomic mutations can lead to cancer formation and affect treatment outcomes and drug resistance. We constructed a... |
| SourceID | doaj unpaywall pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 217 |
| SubjectTerms | Adenomatous polyposis coli Adenomatous Polyposis Coli Protein - genetics Aged Biomedical and Life Sciences Biomedicine BRCA2 protein BRCA2 Protein - genetics Cancer Cancer Research Chemotherapy Clinical outcomes Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Decision trees Deoxyribonucleic acid Development and progression DNA DNA Damage DNA damage response gene DNA repair Drug resistance Drug therapy Evolution Feature selection Female Gene mutations Genetic aspects Health aspects Health Promotion and Disease Prevention Humans Learning algorithms Machine learning Male Medical prognosis Medicine/Public Health Middle Aged Mismatch repair Mutation Neoplasm Staging Oncology Oxaliplatin Oxaliplatin - administration & dosage p53 Protein Patients Phylogenetics Phylogeny Proto-Oncogene Proteins p21(ras) - genetics Research Article Risk groups Sequential somatic mutations Surgical Oncology Survival Tumor evolution Tumor heterogeneity |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDzwOiDcLBQxC4kCj5mE79nF5VF2k9kCL1Jvl2N520W6y2mwE_U38SWYSb9iAVDhwjcd5eMYzn-2ZL4S8ZspBkIpd5LzNIgYQOYIlWBwVAE1MNk0ya3Af8uhYHH5hn8742davvjAnrKMH7gZuP0shBnKXSyUzZoySQqmp8sLwIue5atlLY6k2i6lwfpDLWG5KZKTYr8ELS6xEhqVzrlIRJYMw1LL1_-mTt4LS7wmT_anpLXKjKZfm8puZz7cC08EdcjsgSjruvuQuuebLe-T6UTgzv09-nLTZ0jCT59SUjtoqqqzFnb_ynH44HlNnFuBU6KrLlvUUTAorG-mi6Y7pa9qVUtK6Ab8ClklnJQVQCX0mkwlF2mt0m3DdogmtaOBqreGW1s9wx4Ia97UBzL6m1XcA_ktMwCsjjKDwPhd-EcrALh-Q04OPp-8Po_CLhsiKPF1HMrFp7pn1zuUOkFVqYH3FUuszJadCWkCPTFnhLAAVnnsTs7xQxgPIsNzFKntIdsqq9I8JdS6xQmUujX3BvCiUtFZy0LZLRDzlfESSjcK0DfTl-BeNuW6XMVLoTskalKxbJetkRN72fZYdeceV0u_QDnpJJN5uL4A56mCO-m_mOCIv0Ip0V8Xauw89FpwjFJPwmFetBJJvlJjdc26autaTk88DoTdBaFrBV1oTiiVgrJCvayC5O5AE72CHzRtz1sE71RpgL7L8c8VG5GXfjD0x4670VQMyTAEyliqFWzzqrL8fmSwTmJQMLflgXgyGbthSzi5a7nKkq2QCnru3mUG_Xusq1ez1s-wfNPnkf2jyKbmZtg4D8xx2yc561fhnAEDXxfPW1_wE1EJ-Ww priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LbxMxELZKKvE4IN4EChiExIGuui977QNCKbRqkBqhtki9WY7tpEHJbshmBf1N_Elm9tUuSBHX9XjX6xmPP9sznwl5G0sLk5RvPetM5MUAkT1YgvneGKCJjiZBZDTuQx6P-NG3-Ms5O98ioyYXBsMqG59YOmqbGdwj34OpGpnJmYw_Ln94eGsUnq42V2jo-moF-6GkGLtBtkNkxuqR7f2D0deT9lwhEb5oUmcE38vBOwvMUIYldSJD7gWd6alk8f_XV1-brP4OpGxPU--QW0W61Jc_9Xx-bcI6vEfu1kiTDirTuE-2XPqA3Dyuz9Ifkt-nZRQ1jPA51amlJvMyY3BHMJ3Sz6MBtXoBzoauqihaR8HUMOORLorq-D6nVYolzQvwN2CxdJZSAJtQZzgcUqTDRncKzw2a1orWHK45vNK4Ge5kUG2_F4Dl1zT7BQuCJQbmpR7OrNCeC7eo08MuH5Gzw4OzT0defXWDZ3gSrj0RmDBxsXHWJhYQV6hh3RWHxkVSTLgwgCpjabg1AGBY4rQfJ2OpHYAPw6wvo8ekl2ape0qotYHhMrKh78ax42MpjBFMcGkD7k8Y65OgUZgyNa053q4xV-XyRnBVKVmBklWpZBX0yfu2zrIi9dgovY920EoiIXf5IFtNVT2-VRQCVGM2EVJEsdYSGign0nHNxglLJDTzFVqRqrJbW7eiBpwxhGgCPvOmlEBSjhSjfqa6yHM1PD3pCL2rhSYZ_KXRdRIF9BXyeHUkdzqS4DVMt7gxZ1V7rVxdjbE-ed0WY02MxEtdVoBMLAExCxnCK55U1t_2TBRxDFaGkqQzLjpd1y1JZxclpznSWMYcvrvbjKCrZm1SzW47yv5Dk882__RzcjssXQFGNuyQ3npVuBcAOdfjl7Uf-QPRrn3S priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zb9QwELaqInE8IG4WChiExANNyeE49gNCy1F1kbYPtJX6Zjm2t120myybjej-Jv4kM7naQFX1NR4njj0z_saeg5C3TFrYpHzrWWcijwFE9sAE870UoImOJkFkNJ5Djvf53hH7fhwfb5C23FEzgcWlph3WkzpaznbOfq0_gcB_rARe8A8F6FiBccZgGCcy5B5YQzdgp5JYymHMzm8VElFVqAtAIeOtQtIG0Vz6jt5GVeXz_19rX9i2_nWp7O5V75BbZbbQ6996Nruwde3eI3cbzEmHNZPcJxsue0Bujptb9Yfkz0HlTw2yPqM6s9TkXm4Mng1mJ_Tr_pBaPQe1Q5e1P62jwHQY-0jnZX2RX9A62JIWJWge4F06zSjATugzGo0oJsZGxQrPDTLZkjbZXAt4pXFTPNOg2v4sAdWvaH4GpsECXfQyD_dYGM-pmzeBYutH5HD32-GXPa8p4uAZnoQrTwQmTBwzztrEAvYKNVhgLDQukmLChQF8yaTh1gCUiROnfZakUjuAISa2vowek80sz9xTQq0NDJeRDX2XMsdTKYwRseDSBtyfxPGABO2CKdMkOMc6GzNVGTqCq3qRFSyyqhZZBQPyvuuzqNN7XEn9Gfmgo8TU3NWDfHmiGklXUQigLbaJkCJiWksYoJxIx3WcJnEiYZivkItUHefaKRg15HGMYE3AZ95UFJieI0P_nxNdFoUaHfzoEb1riCY5_KXRTTgFzBVm9OpRbvUoQX-YfnPLzqoVPwXAGOsAxJINyOuuGXuiT17m8hJomATsLGQIr3hSc383M1HE0W0ZWpKeXPSmrt-STU-r7OaY0JJx-O52K0Hnw7pqabY7KbvGSj67zhQ_J7fDSiGgp8MW2VwtS_cCIOgqfVnplb9FSH5U priority: 102 providerName: Scholars Portal – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Jb9QwFLZQkVgOFTtTChiExIFGzWI79nFYqg5Se6Ct1Jvl2J7poJlkNJkI-pv4k7yXjQZQBdf4OXHyFn-23_tCyBumHExSoQuct0nAACIHsAQLgwygiUmmUWIN7kMeHYvDM_b5nJ-3RWFll-3eHUnWkbp2ayn2S4ikEquJYfmbqlgEsOa5yZHOC6z4LB73ZwepDGVXHvPXfoMpqGbq_zMeX5mQfk-W7E9M75LbVb4yl9_MYnFlUjq4R7ZbNEnHjfrvkxs-f0BuHbXn5Q_Jj5M6Uxq8eEFN7qgtgsJa3PXLZ_Tj8Zg6s4SAQtdNpqynYE5Y1UiXVXNEX9KmjJKWFcQUsEo6zykASugzmUwoUl5jyITrFs1nTVue1hJuaf0cdyuocV8rwOsbWnwH0L_C5Ls8wNkTxnPhl20J2OUjcnrw6fTDYdD-niGwIo03gYxsnHpmvXOpA1QVG1hbsdj6RMmpkBaQI1NWOAsghafehCzNlPEAMCx3oUoek628yP1TQp2LrFCJi0OfMS8yJa2VXArlIhFOOR-RqFOYti11Of5BY6HrJYwUulGyBiXrWsk6GpF3fZ9VQ9xxrfR7tINeEkm36wvFeqZbH9ZJDHCMu1QqmTBjFAxQTZUXhmcpTxUM8yVakW4qWPvQoceCc4RhEh7zupZA4o0cM3tmpipLPTn5MhB62wpNC3hLa9pCCfhWyNU1kNwdSEJksMPmzpx1G5lKDZAXGf65YiPyqm_Gnphtl_uiAhmmABVLcK0RedJYf_9lkkRgQjK0pAO_GHy6YUs-v6h5y5Gqkgl47l7nQb-GdZ1q9nov-wdN7vzf3Z-RO3EdGjCbYZdsbdaVfw4wc5O9qKPKT4uOdFQ priority: 102 providerName: Springer Nature |
| Title | Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy |
| URI | https://link.springer.com/article/10.1186/s12885-021-07926-1 https://www.ncbi.nlm.nih.gov/pubmed/33653301 https://www.proquest.com/docview/2502906594 https://www.proquest.com/docview/2496238921 https://pubmed.ncbi.nlm.nih.gov/PMC7923464 https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-021-07926-1 https://doaj.org/article/327105d789834aa98699f9e6a5b75795 |
| UnpaywallVersion | publishedVersion |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: KQ8 dateStart: 20010101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: ABDBF dateStart: 20010101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DIK dateStart: 20010101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central Free customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RPM dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1471-2407 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M48 dateStart: 20010801 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: Springer Nature HAS Fully OA customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: AAJSJ dateStart: 20011201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: C6C dateStart: 20010112 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: U2A dateStart: 20011201 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLbGJnF54H4ZjGEQEg8sW5P4-tiNTSvSqmkXafBiOba7lbVJ1TSC8Zf4kxwnaVgGmkDiJWrtY8exfY6_Y59zjNBbIi0sUh0bWGfigABEDkAF6wQJQBMdD8LYaL8Puddnu8fk4wk9WUC7c1-YZOyrNG66ftn9fFTKbPhhzjcmdlCxumAbOUhX4T2MQSXmMmIB6EFLjAIqX0RLx_397qfSuYiH_hCBz31m_liwtS6V4ft_F9KXVqmrFpTNMeoddKtIJ_riqx6NLq1UO_fQcP6NlYHK-XoxS9bN9yvhH_9HJ9xHd2s4i7vV_HuAFlz6EN3cqw_sH6Efh6WpNoiREdapxSYLMmP8tmN6ij_0u9jqMUg0PK1MdR2G-ezdKvG4qGwEclz5ceK8AKEGbIGHKQZEC2V6vR72Mbe9zIb06ltwHSg2hyqNG_rtEqztlwIUhhnOvoHWMfHWf2ngl29oz5kb1z5oF4_R0c720dZuUN8PERjGo1kgQhNxR4yzlluAdZEG5Y5ExsVSDJgwAF2JNMwaQEmUO90hPJHaAcIx1HZk_AQtplnqniFsbWiYjG3UcQlxLJHCGEEFkzZknQGlyyicTw5l6tjp_gqPkSp1KMFUNQgKBkGVg6DCZfS-KTOpIodcS73p51xD6aN-lwnZ9FTVQkTFEeBBarmQIiZaS2igHEjHNE045RKa-crPWFW50DayS3UZpR4HCnjNm5LCR_5IvWnRqS7yXPUOD1pE72qiQeanm649NaCvfLCwFuVKixJEk2lnz1lH1aIxV4C5_RUDVJJl9LrJ9iW9uV_qsgJoiARYLmQEVTytOK3pmThm3iIacniLB1td185Jh2dl4HQfK5MweO_anFt_Neu6oVlrOPovRvL5v5G_QLejknW9OcUKWpxNC_cScO4sWUU3-AlfRUub2_39A_i3xbZWyz0jeO4RAc-Dzc_wPI4gpRJ3PwEeIacW |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fTxQxEG8IJKIPxv-iKNVofJANt7vdbvtAzCEQTuBiABPeml7bOzDH7nl7G-Qz-Rn8bs7sP1hNLr7wup3udjvT38y0M1NC3jFpQUl1rGedCT0GJrIHLljHG4BposOhHxqN-5CHfb73jX05jU4XyO86FwbDKmtMLIDapgb3yDdAVWNl8kiyT5MfHt4ahaer9RUaurpawW4WJcaqxI59d3UJLly22dsGfr8Pgt2dk897XnXLgGd4HMw84Zsgdsw4a2MLxkGgwUVggXGhFEMuDBhATBpuDejaKHa6w-KB1A70pIlsUYsJNMASC5kE329pa6f_9ag5xohFR9SZOoJvZKAMBCZEgwcfy4B7fksbFpcG_KsabujGv-M2m8Pbe2Q5Tyb66lKPxzf04-4Dcr8ybGm3lMSHZMElj8idw-ro_jH5dVwEbQOgjKlOLDWplxqDG5DJiG73u9TqC8A2Oi2Ddh0FycYES3qRl9ECGS0zOmmWA7zBAqHnCQXbFvr0ej2K1bcRveG5QUme0qpkbAavNO4cN06ott9zcB1mNP0J_scE4wATDxU5jOfMXVTZaFdPyMlt8PApWUzSxD0n1FrfcBnaoOMGzPGBFMaISHBpfd4ZRtEK8WuGKVNVUcfLPMaq8KYEVyWTFTBZFUxW_gr52PSZlDVE5lJvoRw0lFj_u3iQTkeqghMVBmAZRjYWUoRMawkDlEPpuI4GcRRLGOYaSpEqk2kbFFNdHkVoEQr4zNuCAmuAJBhkNNJ5lqne8VGL6ENFNEzhL42ucjZgrrBsWItytUUJIGXazbU4qwokM3W9pFfIm6YZe2LgX-LSHGiYBANdyABe8ayU_mZmwpBjbDS0xK110Zq6dktyflaUUMeqmYzDd9frFXQ9rHmsWW9W2X9w8sX8n14jy3snhwfqoNfff0nuBgUsYFDFKlmcTXP3Cqzd2eB1hSmUqFtGsT_UxLly |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfQkAY8IL4pDGYQEg8sWpo4jv1YOqoVWIXYkPZmObbTFbVJ1TSC_U38k9wlaWgATfAanxPH9-Hf2XdnQl4xaWGR8q1nnQk9BhDZAxfM9xKAJjpM-6HRuA95MuHHX9j78-h8K4u_inbfHEnWOQ1YpSlbHy5tWqu44IcFWFWBmcXgCscy4B74P9cZrG54h8GQD9tzhFj4YpMq89d-neWoqtr_p23eWpx-D5xsT09vkRtlttSX3_R8vrVAje6Q2w2ypINaFO6Say67R3ZPmrPz--THaRU1DRo9pzqz1ORebgzuAGZTejQZUKsXYFzoqo6adRRECzMc6aKsj-sLWqdU0qIE-wISSmcZBXAJfcbjMcXy12g-4blBUVrRpmZrAa80boY7F1TbryVg9zXNv4MDsMRAvMzDlRTGc-EWTTrY5QNyNnp3Njz2mqsaPMPjYO2Jvglix4yzNraAsAINfhYLjAulSLkwgCKZNNwaACxR7LTP4kRqB2DDRNaX4UOyk-WZe0yotX3DZWgD3yXM8UQKY0QkuLR97qdR1CP9DcOUacqY420ac1W5M4KrmskKmKwqJqt-j7xp-yzrIh5XUr9FOWgpsQB39SBfTVWjzyoMAJpFNhZShExrCQOUqXRcR0kcxRKGuY9SpOps1taMqAGPIoRkAj7zsqLAIhwZRvlMdVkUanz6uUP0uiFKc_hLo5ukCZgrrNvVodzrUIKVMN3mjTirxkoVCuAvVvuPJOuRF20z9sTIu8zlJdAwCQhZyABe8aiW_nZmwpBjcDK0xB296ExdtyWbXVQ1zLFsJePw3YONBv0a1lWsOWi17B84-eT_3r5Pdj8djdTH8eTDU3IzqKwEBjnskZ31qnTPAH2uk-eVgfkJgTx7Zg |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Zb9QwELaqrcTxwH0UChiExAPNdnPYsR-Xo9pFaoVoK5Uny7GddulustpsBOUv8SeZSbKhKagCibcoHjuOPTP-xp4ZE_IykhYWqYH1rDOhFwFE9sAEG3gJQBMdpn5oNO5D7u7x0WH04YgdrZHRKhYmmWGTxi3658PPp5XOhgdzuj23aS3qgm8XoF0FRhiDSRzLgHtgB61zBqi8R9YP9z4OP1fBRbGPhwjxKmbmjxU761KVvv93JX1ulbroQdkeo14nV8tsrs--6un03Eq1c5NMVv9YO6ic9stl0jffL6R__B-DcIvcaOAsHdb8d5usuewOubLbHNjfJT_2K1dtUCNTqjNLTe7lxuC2Y3ZM3-0NqdUz0Gh0UbvqOgr8jGGVdFbWPgIFreM4aVGCUgOxoJOMAqKFOuPxmGLObdTZ8L7-F9okii2gSeMmuF1Ctf1SgsGwpPk3sDrm6P2Xebh8Q39O3KyJQTu7Rw523h-8HXnN_RCe4XGw9IRvgthFxlkbW4B1gQbjLgqMC6VIuTAAXSNpuDWAkljs9CCKE6kdIBzD7ECG90kvyzP3kFBrfcNlaIOBSyLHEymMEUxwaX0-SBnbIP6KOZRpcqfjFR5TVdlQgqt6EhRMgqomQfkb5HVbZ15nDrmU-g3yXEuJWb-rF_niWDVKRIUB4EFmYyFFGGktoYMylY5rlsQsltDNZ8ixqg6hbXWXGnLGEAcK-MyLigIzf2ToWnSsy6JQ4_1PHaJXDVGaI7vpJlIDxgqThXUoNzuUoJpMt3glOqpRjYUCzI1XDDAZbZDnbTHWRHe_zOUl0EQSYLmQATTxoJa0dmTCkKNHNJTEHRnsDF23JJucVInTMVdmxOG7Wytp_dWty6Zmq5Xov5jJR_9G_phcCyrRRXeKTdJbLkr3BHDuMnnaqLCfE9mf8Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sequential+and+co-occurring+DNA+damage+response+genetic+mutations+impact+survival+in+stage+III+colorectal+cancer+patients+receiving+adjuvant+oxaliplatin-based+chemotherapy&rft.jtitle=BMC+cancer&rft.au=Lin%2C+Peng-Chan&rft.au=Yeh%2C+Yu-Min&rft.au=Chan%2C+Ren-Hao&rft.au=Lin%2C+Bo-Wen&rft.date=2021-03-02&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-021-07926-1&rft.externalDBID=ISR&rft.externalDocID=A655222381 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |